{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-001400","form_type":"8-K","ticker":"AYTU","cik":"0001385818","company_name":"AYTU BIOPHARMA, INC","filed_at":"2023-01-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.711293+00:00","generated_at":"2026-06-20T19:28:58.802868+00:00","sec_items":["3.03","5.03","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Aytu BioPharma enacts 1-for-20 reverse stock split to regain Nasdaq $1.00 bid compliance","bullets":["1-for-20 reverse split reduces outstanding shares from ~68.8M to ~3.4M.","Company must maintain closing bid ≥$1.00 for 10 consecutive days by May 22, 2023 to comply with Nasdaq.","Proportional adjustments to warrants, options, and equity plan pool; no fractional shares—cash in lieu.","New CUSIP 054754858; shares continue trading under ticker AYTU on Nasdaq."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-001400","json":"https://secwatch.observer/filing/0001104659-23-001400.json","markdown":"https://secwatch.observer/filing/0001104659-23-001400.md","text":"https://secwatch.observer/filing/0001104659-23-001400.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1385818/000110465923001400/0001104659-23-001400-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1385818/000110465923001400/tm231530d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T19:28:58.802868+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"baf071d6e8e91947483d22bd53d3fd590b9202b3","claim":"AYTU BIOPHARMA, INC: Approved a 1-for-20 reverse stock split via a Certificate of Amendment to the Certificate of Incorporation, effective January 6, 2023 (effective 2023-01-06).","evidence_excerpt":"On January 4, 2023, the Board of Directors of Aytu BioPharma, Inc. (“the Company” or “Aytu”) approved a 1-for-20 reverse stock split of the Company's common stock, which will be effective at 12:01 a.m. Eastern Time on Friday, January 6, 2023 pursuant to a Certificate of Amendment (the “Certificate of Amendment”) to the Company’s Certificate of Incorporation.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1385818/000110465923001400/0001104659-23-001400-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2023-01-06"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}